Onset Dermatologics announces nationwide availability of Tretin-X Cream 0.075%

Onset Dermatologics, LLC, a leader in developing and commercializing prescription products for improving skin health, announced the nationwide availability of Tretin-X^® (tretinoin, USP) Cream 0.075%. Tretin-X^® Cream is a prescription product for the topical treatment of acne.

"Tretin-X^® Cream 0.075% offers dermatologists an option for dosing flexibility with the same elegant cream vehicle as our popular Tretin-X^® 0.0375%," said Robert Moccia, President, Onset Dermatologics and CEO, Precision Dermatology. "Dermatology practitioners might consider Tretin-X^® 0.075% for an acne patient who is ready to move from a lower concentration of tretinoin to a higher concentration or whose disease severity requires a greater tretinoin strength." Tretin-X^® Cream 0.075% was approved by the U.S. Food and Drug Administration in 2013 and has been available in limited geographic areas since November 2013. The cream vehicle is free of known irritants, such as parabens, alcohol, and propylene glycol.

"Topical retinoids, such as Tretin-X^®, are the cornerstone of acne therapy because they reduce inflammation and the formation of comedones (whiteheads and blackheads) which are the hallmark of the disease," says Hilary Baldwin, MD, Associate Professor of Dermatology at State University of New York - Downstate. "As dermatologists, we know patients will adhere to therapy better when they like the way the product feels. Many of my acne patients with concerns about tolerability prefer a cream vehicle, instead of a gel."

Tretin-X^® Cream is the fastest growing prescription topical retinoid over the past year, according to IMS Health.